Exelixis, Inc. (EXEL) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Loading...

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices

Follow our journey and product updates

Product

Overview Company evaluations Research a topic

Company

About us Blog Contact

Legal

Terms Privacy Policy

Exelixis, Inc. (EXEL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Exelixis, Inc. (EXEL)

Company Performance

Current Price

as of Dec 04, 2024

$35.77

P/E Ratio

22.80

Market Cap

$10.22B

Description

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Metrics

Overview

HQAlameda, CA
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerEXEL
Price$35.77+1.45%

Trading Information

Market cap$10.22B
Float97.50%
Average Daily Volume (1m)1,946,106
Average Daily Volume (3m)2,137,848
EPS$1.60

Company

Revenue$2.08B
Rev growth (1yr)14.33%
Net income$117.97M
Gross margin96.79%
EBITDA margin36.20%
EBITDA$195.30M

EV$6.57B
EV/Revenue3.16
P/E22.80
P/S5.01
P/B4.49

Documents

SEC Filings

8-K (2024-10-29)

8-K (2024-10-15)

8-K (2024-08-06)

8-K (2024-06-03)

8-K (2024-05-20)

8-K (2024-05-10)

8-K (2024-04-30)

8-K (2024-03-29)

8-K (2024-02-06)

8-K (2024-01-08)

8-K (2023-12-20)

8-K (2023-11-01)

8-K (2023-09-19)

8-K (2023-08-23)

8-K (2023-08-01)

8-K (2023-07-24)

8-K (2023-06-05)

8-K (2023-05-09)

8-K (2023-05-08)

8-K (2023-04-13)

8-K (2023-03-22)

8-K (2023-03-20)

8-K (2023-02-07)

8-K (2023-01-09)

10-Q (2024-10-29)

10-Q (2024-08-06)

10-Q (2024-04-30)

10-Q (2023-11-01)

10-Q (2023-08-01)

10-Q (2023-05-09)

10-K (2024-02-06)

10-K (2023-02-07)

Factset Street Account

StreetAccount Metrics Recap - Exelixis Q3 Earnings ($21.02, 0.00) (2023-11-01T20:24:40Z)

StreetAccount Earnings Call Q&A Summary: Exelixis Q3 ($ 21.02, 0.00) (2023-11-02T00:01:21Z)

StreetAccount Consensus Metrics Preview - Exelixis Q3 Earnings ($20.14, -0.85) (2023-10-27T18:53:36Z)

Exelixis reports Q3 EPS $0.10 ex-items vs FactSet $0.12 [15 est, ($0.13)-0.32] ($21.02, 0.00) (2023-11-01T20:17:26Z)

Exelixis initiated buy at BTIG ($23.34, 0.00) (2023-12-19T10:03:27Z)

Exelixis announces initial results from an expansion cohort of STELLAR-001 evaluating single-agent zanzalintinib in patients with previously treated clear cell renal cell carcinoma (ccRCC) ($21.02, 0.00) (2023-11-10T14:02:24Z)

CABINET trial of Exelixis's CABOMETYX in patients with previously treated neuroendocrime tumours meets primary objectives ($21.11, 0.00) (2023-10-22T09:29:38Z)

Earnings Calls

Earnings Report 2024Q3

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report (2023-11-01)

Earnings Report (2023-08-01)

Wikipedia

Factset

Factset Business Description